Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays

Roche announced today,that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF. These in vitro diagnostic immunoassays are for the measurement of the ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of dementia.

Currently, the diagnosis of AD is largely based on clinical symptoms, including cognitive testing, with a significant number of patients diagnosed when their disease has already advanced. A diagnosis of AD based on cognitive measures alone is only correct in 70 – 80 percent of cases. Measuring biomarkers with CSF immunoassays, associated with AD pathology, increases certainty of a diagnosis of AD and can help to evaluate the progression of the disease. The Breakthrough Device Designations are for indication of use with Elecsys β-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF in concordance with amyloid PET visual read result and risk of cognitive or functional decline. The Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these medical devices.

“We are excited about FDA’s recognition of the potential clinical benefit the Elecsys CSF assays can bring to clinicians, laboratories and their patients in diagnosing AD at an early stage,” said Roland Diggelmann, CEO of Roche Diagnostics. “Roche was one of the first companies to use biomarkers in clinical trials and we will continue to explore high-performing diagnostic and disease-monitoring solutions.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Sequencing and Life Science. (2019, June 18). Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays. News-Medical. Retrieved on October 07, 2024 from https://www.news-medical.net/news/20180724/Roche-receives-Breakthrough-Device-Designation-from-FDA-for-new-Alzheimers-disease-assays.aspx.

  • MLA

    Roche Sequencing and Life Science. "Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays". News-Medical. 07 October 2024. <https://www.news-medical.net/news/20180724/Roche-receives-Breakthrough-Device-Designation-from-FDA-for-new-Alzheimers-disease-assays.aspx>.

  • Chicago

    Roche Sequencing and Life Science. "Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays". News-Medical. https://www.news-medical.net/news/20180724/Roche-receives-Breakthrough-Device-Designation-from-FDA-for-new-Alzheimers-disease-assays.aspx. (accessed October 07, 2024).

  • Harvard

    Roche Sequencing and Life Science. 2019. Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays. News-Medical, viewed 07 October 2024, https://www.news-medical.net/news/20180724/Roche-receives-Breakthrough-Device-Designation-from-FDA-for-new-Alzheimers-disease-assays.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument